ImmunityBio Inc (IBRX) concluded trading on Thursday at a closing price of $2.90, with 4.25 million shares of worth about $12.33 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.89% during that period and on March 13, 2025 the price saw a gain of about 1.05%. Currently the company’s common shares owned by public are about 852.74M shares, out of which, 88.78M shares are available for trading.
Stock saw a price change of -3.01% in past 5 days and over the past one month there was a price change of -8.52%. Year-to-date (YTD), IBRX shares are showing a performance of 13.28% which decreased to -43.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $10.53 during that period. The average intraday trading volume for ImmunityBio Inc shares is 6.28 million. The stock is currently trading -8.04% below its 20-day simple moving average (SMA20), while that difference is down -4.86% for SMA50 and it goes to -32.80% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 852.74M outstanding shares and institutions hold larger chunk of about 9.91% of that.
The stock has a current market capitalization of $2.47B and its 3Y-monthly beta is at 0.43. It has posted earnings per share of -$0.63 in the same period. It has Quick Ratio of 3.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 6.41% while standing at 10.24% over the month.
Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of -0.14 in the current quarter, while forecast for next quarter EPS is -0.13 and it is -0.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.15 which is -0.12 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 2.26% while it is estimated to increase by 41.58% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on March 06, 2025 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by BTIG Research stated ImmunityBio Inc (IBRX) stock as a Buy in their note to investors on January 10, 2025, suggesting a price target of $6 for the stock. On May 12, 2023, Piper Sandler Downgrade their recommendations, while on August 03, 2022, Jefferies Initiated their ratings for the stock with a price target of $8.
